LENZ LENZ Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1815776 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-29.4%
TTM net income YoY-138.2%
TTM EPS YoY-119.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin82.0%
Operating margin-1,211.2%
Net margin-1,135.0%
FCF margin-1,033.3%
EBITDA margin-1,207.6%
Returns
ROE-72.7%
ROA-66.7%
ROIC (approx.)-71.7%
Asset turnover0.06x
Leverage & solvency
Liabilities / assets8.5%
Debt / equity0.00x
Current ratio11.66x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.91x
Accruals ratio-6.0%
Payout ratio—
Capex / revenue0.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $19.09M | $0 | — | — | — |
| Cost of revenue | $418,000 | $0 | — | — | — |
| Gross profit | $18.67M | $0 | — | — | — |
| R&D expense | $18.67M | $29.80M | $59.50M | $72.79M | $37.93M |
| SG&A expense | $91.14M | $28.81M | $12.93M | $32.85M | $22.51M |
| Operating income | -$91.14M | -$58.61M | -$72.43M | -$105.64M | -$60.44M |
| Pretax income | -$81.62M | -$49.77M | -$70.15M | — | — |
| Income tax | $502,000 | $1,000 | -$179,000 | $0 | $0 |
| Net income | -$82.13M | -$49.77M | -$69.97M | -$101.05M | -$70.76M |
| EBITDA | -$90.85M | -$58.55M | -$72.41M | -$103.29M | -$59.71M |
| EPS (basic) | -2.85 | -2.34 | -35.71 | -1.84 | -2.45 |
| EPS (diluted) | -2.85 | -2.34 | -35.71 | -1.84 | -2.45 |
| Weighted avg. shares (diluted) | 28.81M | 21.28M | 1.96M | 54.87M | 28.92M |
| Balance sheet | |||||
| Cash & equivalents | $25.18M | $20.16M | $35.14M | $44.44M | $376.98M |
| Short-term investments | — | — | $30.65M | $220.50M | $0 |
| Receivables | $329,000 | $0 | — | — | — |
| Inventory | $2.94M | $0 | — | — | — |
| Current assets | $301.41M | $211.92M | $67.24M | $275.37M | $381.74M |
| PP&E, net | $1.19M | $651,000 | $54,000 | $22.63M | $6.51M |
| Total assets | $305.88M | $215.30M | $70.38M | $321.90M | $401.99M |
| Current liabilities | $21.19M | $10.41M | $18.51M | $13.04M | $12.14M |
| Total liabilities | $21.54M | $11.22M | $19.70M | $25.61M | $17.94M |
| Shareholders' equity | $284.34M | $204.08M | -$92.71M | -$24.17M | $384.05M |
| Shares outstanding | 31.34M | 27.52M | 1.97M | 58.22M | 58.01M |
| Cash flow statement | |||||
| Operating cash flow | -$69.17M | -$59.39M | -$60.38M | -$87.98M | -$52.85M |
| Capital expenditure | $827,000 | $468,000 | $30,000 | $6.59M | $5.74M |
| Free cash flow | -$70.00M | -$59.86M | -$60.41M | -$94.57M | -$58.59M |
| Investing cash flow | -$75.67M | -$154.48M | -$29.62M | -$241.86M | -$5.74M |
| Financing cash flow | $149.75M | $199.00M | $80.70M | $597,000 | $417.47M |
| Depreciation & amortization | $287,000 | $58,000 | $15,000 | $2.35M | $734,000 |
| Stock-based compensation | $12.55M | $6.37M | $1.34M | $13.53M | $7.87M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.